BioPredictive S.A.S – Trademark Portfolio

Entity Type: 16

BioPredictive S.A.S holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 5 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 2 trademarks are registered and 2 are pending. Notable registered marks include FIBROMAX and FIBROTEST. The owner is based in Paris.

218 Boulevard Saint-Germain

Paris 75007 , FR

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

BioPredictive S.A.S's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

44
Medical Services (5 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does BioPredictive S.A.S have?

BioPredictive S.A.S has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 pending, 1 abandoned.

What trademark classes does BioPredictive S.A.S file in?

BioPredictive S.A.S files trademarks across 2 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 42 (Computer & Scientific). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.

What are BioPredictive S.A.S's most well-known trademarks?

BioPredictive S.A.S's registered trademark portfolio includes well-known marks such as FIBROMAX and FIBROTEST. These are among 2 currently registered trademarks in the portfolio.

What is BioPredictive S.A.S's trademark registration success rate?

BioPredictive S.A.S has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 2 applications are pending review.